The Challenge
Eating disorders have the highest mortality rate of any mental health condition. Despite this severity, conventional treatment — typically a combination of SSRIs and cognitive behavioral therapy — achieves full remission in only about 30-50% of patients with anorexia, and relapse rates are high even among those who initially respond. The treatment gap is enormous.
The reason lies in the neurology. Eating disorders are not simply about food or weight — they involve fundamental dysregulation of serotonin signaling (which governs appetite, mood, and body image perception), rigid patterns in the default mode network (which sustains the obsessive self-referential thinking characteristic of body dysmorphia), and often deeply embedded trauma that drives the disordered relationship with food and body.
Conventional treatment addresses these components one at a time: SSRIs for serotonin, CBT for thought patterns, and separate trauma therapy. Ibogaine's pharmacological breadth addresses all three simultaneously — serotonin receptor modulation, default mode network disruption, and deep psychological processing in a single treatment session.
Serotonin (5-HT) is the master regulator of appetite, satiety, mood, and body image perception. Dysregulated serotonin signaling is documented in all major eating disorders — reduced 5-HT activity in bulimia and binge eating, altered 5-HT receptor binding in anorexia. Ibogaine acts on multiple serotonin receptor subtypes, modulating the system at its foundation.
Conditions Addressed
Characterized by restrictive eating, distorted body image, and extreme fear of weight gain. The serotonergic dysfunction in anorexia is well-documented, and ibogaine's 5-HT receptor modulation targets this directly. The deep introspective processing may also address the trauma and control dynamics that often underlie anorexia. Research is early — mechanistic rationale is strong, but clinical data is limited.
Cycles of binge eating and compensatory behaviors (purging, fasting, excessive exercise). Bulimia involves dysregulated serotonin-mediated appetite signaling and impulse control deficits. Ibogaine addresses both: serotonin receptor modulation for appetite regulation and dopaminergic reset for impulse control. Note: electrolyte screening is essential before treatment.
Recurrent episodes of eating large quantities of food without compensatory behaviors. Shares neurological features with substance addiction — the same dopaminergic reward hijacking that drives drug seeking drives compulsive eating. Ibogaine's demonstrated anti-addictive properties and dopamine system reset have direct relevance to the compulsive eating cycle.
Many eating disorders have trauma at their root — the disordered eating is a coping mechanism for unresolved pain. Ibogaine's visionary phase facilitates deep trauma processing that traditional talk therapy may take years to access. By addressing the root trauma, the need for the eating disorder as a coping strategy can diminish naturally.
Research Transparency
We are committed to honesty about the state of evidence. The research supporting ibogaine for eating disorders is early and primarily mechanistic. The strongest evidence comes from: (1) well-documented serotonergic activity relevant to appetite and body image regulation; (2) demonstrated default mode network disruption relevant to rigid self-referential thinking; (3) established anti-addictive properties relevant to the compulsive aspects of eating disorders; and (4) published case reports of psychedelic-assisted improvements in eating disorder symptoms.
What the evidence does not include: randomized controlled trials of ibogaine specifically for eating disorders, large-scale outcome data, or head-to-head comparisons with established eating disorder treatments (CBT-E, FBT, SSRIs). We do not claim that ibogaine is a proven treatment for eating disorders. What we do say is that the mechanistic rationale is compelling, the parallels with other conditions ibogaine treats are strong, and for patients who have exhausted conventional options, this is a scientifically grounded path worth exploring under comprehensive medical supervision.
Treatment Approach
Eating disorder patients undergo additional screening beyond our standard protocol: comprehensive electrolyte panel (critical for purging behaviors), nutritional status assessment, cardiac evaluation with attention to QTc prolongation risk in malnourished patients, and bone density screening for long-term anorexia patients. Medical stability is required before ibogaine treatment.
Patients with severe malnutrition or active purging may need a stabilization period before ibogaine is safe to administer. Our medical team works with your existing treatment providers to ensure nutritional status supports safe ibogaine metabolism and cardiac function.
The ibogaine session is administered under continuous cardiac monitoring with physician supervision. Eating disorder patients often report profound insights during the visionary phase related to body image, self-worth, trauma, and the relationship between food and emotional regulation.
Post-treatment integration for eating disorder patients includes: body-image processing, nutritional counseling aligned with recovery goals, somatic therapy for embodiment, and structured psychotherapy addressing the specific thought patterns and triggers that sustain disordered eating.
Our 90-day integration program includes eating disorder-specific sessions: CBT for body image distortion, meal planning support, trigger identification and management, and coordination with your existing treatment team for continuity of care after you return home.
Common Questions
Not sure if you qualify? Take our confidential eligibility assessment or explore our clinical outcomes.
100% Confidential · No Obligation · Response Within 24 Hours
100% Confidential · No Obligation · Available 7 Days a Week
Latest Research & News
Feb 26, 2026
A woman suffering from treatment-resistant depression for nineteen years walked into a clinical trial at Imperial Colleg...
Read Article →Feb 26, 2026
The field of psychedelic medicine took another significant step forward this week. A Phase II clinical trial published t...
Read Article →Feb 21, 2026
Introduction If you're taking Effexor (venlafaxine) and considering ibogaine treatment , understanding the critical safe...
Read Article →Feb 18, 2026
Prozac (fluoxetine) has been one of the most prescribed antidepressants since the 1980s. If you're taking Prozac and exp...
Read Article →
